Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IVT PCV-25 in Healthy Adults
NCT05540028Phase 1Completed
- Sponsor
- Inventprise
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IVT PCV-25 in pneumococcal disease (2 arms), sponsored by Inventprise. Primary endpoints: Solicited local and systemic adverse events at Day 8, Clinically significant hematological and biochemical measurements at Day 8 and 3 more. Started Sep 2022; status: completed.
02
Drugs
IVT PCV-25
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05540028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540028.